UK Uveitis Therapeutics Market Report 2023 to 2030

UK Uveitis Therapeutics Market Analysis

$ 3999

UK Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).

ID: IN10GBRD007 CATEGORY: Rare Diseases GEOGRAPHY: UK AUTHOR: Sakshi Mantri

Buy Now

UK Uveitis Therapeutics Market Analysis Summary

UK Uveitis Therapeutics Market is valued at around $41.6 Mn in 2022 and is projected to reach $49.9 Mn by 2030, exhibiting a CAGR of 2.3% during the forecast period 2023-2030.

Uveitis is an inflammation of the uvea, which includes the iris, ciliary body, and choroid as its middle layer of ocular tissue. The most typical extra-articular symptom of spondyloarthritis is uveitis (SpA) Anatomically speaking, uveitis can be anterior, middle, posterior, or widespread. Typically, uveitis is described as an inflammation of the iris and anterior chamber; intermediate uveitis is described as an inflammation of the ciliary body and vitreous humour (the jelly-like substance that fills the anterior portion of the eye); and posterior uveitis is described as an inflammation of the retina, choroid, or the optic disc (where the optic nerve enters the retina). Panuveitis, also known as diffuse uveitis, refers to inflammation throughout the whole uveal tract. Light sensitivity, red eyes, eye pain, or vision issues are some of the signs of uveitis. Eye drops containing corticosteroids are typically advised by doctors to treat uveitis and the ensuing inflammation. If the drops are ineffective, a physician can advise a tablet or an injection. Eye drops are first needed for uveitis. Injections, oral medicines, or immunosuppressive treatments are typically used to treat intermediate, posterior, or pan-uveitis. In some circumstances, a surgeon can also be required to remove the gel-like substance from the troubled eye. Technology advancements in the industry have contributed to the creation of medications with increased effectiveness and fewer side effects, combined with higher spending for healthcare, which together are serving as a potential driver of the uveitis therapeutics market. Allergan (now part of Novartis AG).

Market dynamics

Market Drivers

Focus on Personalized medicine

Personalized medicine techniques like genetic profiling and biomarker discovery are becoming more popular in the market for uveitis. These techniques help to enhance results, reduce side effects, and tailor treatment regimens for particular patients.

Technological developments

The accuracy of diagnoses and the efficacy of treatments are being improved through new diagnostic tools, imaging techniques, and therapeutic approaches.

Increasing healthcare spending

Increasing healthcare spending, especially in emerging economies, is enabling the creation and accessibility of cutting-edge Uveitis treatment options

Market Developments

In preclinical models, the efficacy and safety of BNSO-1 are clearly demonstrated. Before the end of 2023, BNSO plans to start a phase I/IIa clinical research with individuals who have chronic anterior uveitis. For this indication, BNS has secured FDA orphan status, and if the clinical trials are successful, BNS anticipates a faster 505b2 regulatory approval pathway.

Notable deals in Restraints in the Uveitis therapeutics market

A deal has been reached to form a new Ophthalmic company called BNS Ophthalmics between RAFARM, a Greek pharmaceutical company and recognised European manufacturer with expertise in ophthalmics, and BioNanoSim (BNS), an Israeli nanotechnology drug discovery and development company co-founded by Prof. Simon Benita and Yissum, the Transfer Technology and IP company of The Hebrew University of Jerusalem (BNSO). In order to meet the significant unmet ophthalmic needs of patients worldwide, BNSO will develop, produce, and market a variety of novel pharmaceutical solutions for the eyes.

Restraints in the Uveitis therapeutics market

The high cost of therapy

The high expense of uveitis therapy is a key barrier for the industry. For instance, biologics can be very expensive, making it difficult for patients to access these medicines.

Medication side-effects

Immunosuppressants and corticosteroids are two examples of drugs used to treat anterior uveitis that may have long-term dangers and adverse effects. It is crucial to effectively track and manage these risks.

Lack of standardized treatment recommendations

Due to the lack of defined treatment recommendations, several therapy approaches are employed to treat uveitis. This could result in less than ideal management and make it challenging to compare the results of various treatments.

Key players

Novartis Pfizer AbbVie Johnson & Johnson Amgen Celgene UCB Takeda Pharmaceutical Company Vertex Pharmaceuticals Gilead Sciences

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market segmentations for UK Uveitis therapeutics market

By Disease Type

Anterior Uveitis
Intermediate Uveitis
Panuveitis
Posterior Uveitis

By Distribution Channel

Drug Stores and Retail Pharmacies
Hospital Pharmacies
Online
Others

By diagnosis

Laboratory tests such as blood tests
Imaging tests such as an MRI or CT scan

By treatment

Medicine

Corticosteroid
Antimicrobial
Immunosuppressants

Surgery

Therapy

Phototherapy
Laser therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.